Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-1463
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease ; volume:126 ; number:3 ; day:28 ; month:1 ; year:2019 ; pages:299-308 ; date:3.2019
Journal of neural transmission ; 126, Heft 3 (28.1.2019), 299-308, 3.2019
- Creator
-
Hattori, Nobutaka
Takeda, Atsushi
Takeda, Shinichi
Nishimura, Akira
Kitagawa, Tadayuki
Mochizuki, Hideki
Nagai, Masahiro
Takahashi, Ryosuke
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00702-018-1964-3
- URN
-
urn:nbn:de:101:1-2019040100445597529643
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hattori, Nobutaka
- Takeda, Atsushi
- Takeda, Shinichi
- Nishimura, Akira
- Kitagawa, Tadayuki
- Mochizuki, Hideki
- Nagai, Masahiro
- Takahashi, Ryosuke
- SpringerLink (Online service)
Other Objects (12)
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study
Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study
Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study
Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease